ARCH Venture Partners X, LLC - Sep 19, 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
10%+ Owner
Signature
ARCH VENTURE FUND X, L.P.; By: ARCH Venture Partners X, L.P, Its: General Partner; By: ARCH Venture Partners X, LLC, Its: General Partner; By: /s/ Mark McDonnell, attorney-in-fact
Stock symbol
NMRA
Transactions as of
Sep 19, 2023
Transactions value $
$25,500,000
Form type
4
Date filed
9/20/2023, 06:16 AM
Previous filing
Sep 14, 2023
Next filing
Dec 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NMRA Common Stock Conversion of derivative security +684K 684K Sep 19, 2023 By ARCH Venture Fund VII, L.P. F1, F2
transaction NMRA Common Stock Conversion of derivative security +1.14M 1.14M Sep 19, 2023 By ARCH Venture Fund VIII Overage, L.P. F1, F3
transaction NMRA Common Stock Conversion of derivative security +6.9M +129.84% 12.2M Sep 19, 2023 By ARCH Venture Fund X, L.P. F1, F4, F6
transaction NMRA Common Stock Conversion of derivative security +6.58M +123.84% 11.9M Sep 19, 2023 By ARCH Venture Fund X Overage, L.P. F1, F5, F6
transaction NMRA Common Stock Conversion of derivative security +2.12M 2.12M Sep 19, 2023 By ARCH Venture Fund XII, L.P. F1, F7
transaction NMRA Common Stock Purchase $25.5M +1.5M +70.62% $17.00* 3.62M Sep 19, 2023 By ARCH Venture Fund XII, L.P. F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Series A-1 Preferred Stock Conversion of derivative security -684K -100% 0 Sep 19, 2023 Common Stock 684K By ARCH Venture Fund VII, L.P. F1, F2
transaction NMRA Series A-1 Preferred Stock Conversion of derivative security -1.14M -100% 0 Sep 19, 2023 Common Stock 1.14M By ARCH Venture Fund VIII Overage, L.P. F1, F3
transaction NMRA Series A-2 Preferred Stock Conversion of derivative security -6.9M -100% 0 Sep 19, 2023 Common Stock 6.9M By ARCH Venture Fund X, L.P. F1, F4, F6
transaction NMRA Series A-2 Preferred Stock Conversion of derivative security -6.58M -100% 0 Sep 19, 2023 Common Stock 6.58M By ARCH Venture Fund X Overage, L.P. F1, F5, F6
transaction NMRA Series B Preferred Stock Conversion of derivative security -2.12M -100% 0 Sep 19, 2023 Common Stock 2.12M By ARCH Venture Fund XII, L.P. F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
F2 Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F3 Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F4 Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F5 Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6 ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.
F7 Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Remarks:

This Form 4 is filed jointly by ARCH X, AVP X LP, ARCH X Overage, AVP X Overage LP, AVP X LLC, ARCH VII, AVP VII LP, AVP VII LLC, ARCH VIII Overage, AVP VIII LLC, ARCH XII, AVP XII LP, AVP XII LLC, Robert Nelsen, Steven Gillis, Keith Crandell, Clinton Bybee (collectively, the "Reporting Persons"). Kristina Burow has direct ownership of Series A-1 Preferred Stock and is filing her own Form 4 separately. Form 2 of 2